Love Nephrology and baseball.Partner Dallas Nephrology Associates.This is a personal account. Teaching/practicing/learning Nephrology for living.
Dallas, TX,Comerio,PR
Joined July 2013
- Tweets8.1K
- Following2.1K
- Followers1.9K
- Likes15.6K
Dr.Roberto Collazo-Maldonado retweeted
Drug induced TMA: eculizumab improves kidney function in this complex scenario. Barbarini et al. Nephrol Dial Transplant, 2026.
doi.org/10.1093/ndt/gfag246
Thank you, @LilianPalma412, for highlighting our study, just out in @NDTsocial! 🔥#KidneyWk @asnpublications
The only study looking at C5 inhibition with 100% of patients having biopsy-proven TMA!
@MayoClinicNeph @MBarbarini
Dr.Roberto Collazo-Maldonado retweeted
Complete summary and more of IgA nephropathy using mass spectrometry.
1. Majority of IgA is IgA1.
2. Smaller amounts of IgA2 are also present.
3. Both IgA1 and IgA2 colocalize with IgG, showing that the deposits are composed of IgA1/IgG and IgA2/IgG.
4. Dominant IgG subclass is IgG1.
5. J chain that binds monomers of IgA into dimers is present in majority of cases, indicating that the IgA is mucosal derived (as circulating IgA is monomer and doesn’t have J chain)
6. Absence of PIGR indicates that IgA is not derived from secretions such as saliva, tears, etc. PIGR is a peptide in IgA (present in secretions), that prevent the breakdown of IgA by bacteria.
Taken together: IgA immune complexes in IgA nephropathy are made up of antigenic (galactose-deficient) mucosal-derived IgA and IgG.
7. Complement: Large amounts of C3 and C9 indicating alternative and terminal pathways of complement activation.
8. Minimal classical/no lectin pathway proteins.
9. Some correlation with MESTC score but bottom line= all IgA nephropathy shows lots of C3 and C9.
10. Abundant CFHR5 indicating that there is breakdown of C3 into inactive C3=iC3b.
11. Complement is a major player in the inflammatory process in IgA nephropathy.
kidney-international.org/art…
Dr.Roberto Collazo-Maldonado retweeted
Timing and sequencing of Guideline-Directed Medical Therapy (GDMT) in CKD ca. 2026 from @asnpublications
#Nephpearls #KidneyWk
👉 pubmed.ncbi.nlm.nih.gov/4233…
Dr.Roberto Collazo-Maldonado retweeted
sadly unaffordable - the last column is estimated annual costs …and we have no idea when they should/can be stopped?
more on the nephjc blog nephjc.com/news/2026/10/21/k…
#KidneyWK
Dr.Roberto Collazo-Maldonado retweeted
Thank you, @LilianPalma412, for highlighting our study, just out in @NDTsocial! 🔥#KidneyWk @asnpublications
The only study looking at C5 inhibition with 100% of patients having biopsy-proven TMA!
@MayoClinicNeph @MBarbarini
Dr.Roberto Collazo-Maldonado retweeted
💬 Editorial by Kai-Uwe Eckardt, MD, and Mark Koury, MD: #SGLT2 inhibitors were developed for glycemic control but also consistently increase hemoglobin and hematocrit across patients with cardiovascular disease, heart failure, or chronic kidney disease, with or without diabetes. This additional effect may contribute to multimodal anemia management while accompanying the established cardiovascular and kidney benefits of this drug class.
ja.ma/4ecSMF1
#KidneyWk @ASNKidney
Dr.Roberto Collazo-Maldonado retweeted
Armanni-Ebstein Lesions Associated With SGLT2 Inhibitor Therapy
kireports.org/article/S2468-…
Dr.Roberto Collazo-Maldonado retweeted
Yes. Competing outcome of death is monumentally higher than ESRD. This is why gfr slope reduction or other kidney enpoints for HTN/diabetes ckd misses the boat. Honestly, if you are a nephrologist, doing primary and secondary prevention for CVD through risk factor modification is way higher value than worrying about Hgb, product, or Vit D
Dr.Roberto Collazo-Maldonado retweeted
Apparent resistant hypertension affected about 40% of people with CKD and type 2 dm in CONFIDENCE. Finerenone plus empagliflozin lowered BP more than either drug alone, on par with spironolactone but without its hyperkalemia burden. Now in JACC: Advances: sciencedirect.com/science/ar…
Dr.Roberto Collazo-Maldonado retweeted
Most people with CKD don't make it to dialysis. They die of CVD.
Dr.Roberto Collazo-Maldonado retweeted
For those of you who slept in here is @jordy_bc's speech
Dr.Roberto Collazo-Maldonado retweeted
The most important figure in the new USRDS Annual Data Report. #KidneyWk
Dr.Roberto Collazo-Maldonado retweeted
Don’t forget to checkout our oral presentation tomorrow. @basmeomeo will discuss the concept of CLL or renal significance.
Familiar withMGRS? How about CLL of renal significance? Delighted to present our work on this concept at ASN 2026! See you at 4.30-6.00 PM 10/23/26. More details below ⬇️ @LadanZand @onconephsociety
Dr.Roberto Collazo-Maldonado retweeted
Thanks a lot, Hurricane Helene. No matter, the home dialysis train cannot be stopped. #KidneyWk
Dr.Roberto Collazo-Maldonado retweeted
Presented at #KidneyWk:
In patients with IgA nephropathy, atacicept, a human TACI–Fc fusion protein that modulates B-cell activity, slowed and stabilized the decline in the eGFR as compared with placebo. Full phase 3 ORIGIN 3 trial results: nej.md/4dJYTAo
@ASNKidney
ALT A graph shows the mean change in the estimated glomerular filtration rate (GFR) from baseline through week 104 for atacicept and placebo.
Dr.Roberto Collazo-Maldonado retweeted
Presented at #KidneyWk:
In a phase 3, double-blind, randomized trial involving patients with IgA nephropathy, sibeprenlimab stabilized the eGFR slope over 24 months, consistent with a reduced risk of kidney-function decline. Full VISIONARY trial results: nej.md/4z3QsZg
@ASNKidney
ALT A graph shows the least-squares mean change in the estimated glomerular filtration rate (eGFR) from baseline to 24 months, analyzed by the repeated-measures model, in the full analysis population, which included all patients who underwent randomization.
Dr.Roberto Collazo-Maldonado retweeted
“A Phase 2 Open-Label Trial Evaluating the Efficacy and Safety of Daratumumab in Treatment of Patients with Active Lupus Nephritis (LN)”
#ASNKidneyWeek2026 and discuss an exciting Mayo Clinic research project!
@LadanZand @fervenzaf @mvargas07 @AnilaCara @wisit661
Dr.Roberto Collazo-Maldonado retweeted
💙 An inspiring start to #KidneyWk 2026!
Dr. Samir Parikh @samirparikhmd, ASN President, opens his Presidential Address with a powerful message about COURAGE.
A reminder of the courage it takes to lead, innovate, and advance kidney care. 🫘
#UTSWNephroly @UTSWInternalMed
Dr.Roberto Collazo-Maldonado retweeted
More data is good. And I appreciate intent of the article. Nelson Leung whos my friend and colleague (and writers the light chain cast nephropathy management section on UpToDate) is on the paper. My problem is the conclusion. Thats way behind and too confident for what a retrospective study can reveal and if physicians or patients actually take that to heart and implement or if insurance rejects approval can and will cause harm. The tweet that I saw promoted the conclusion. Thats what people see. Not the previous sentence that there was benefit in newly diagnosed.
I don’t remember the last time we plexed a patient with relapsed MM with cast nephropathy. It’s really uncommon to have that presentation in today’s Myeloma practice. I’m mainly concerned about newly diagnosed MM presenting with acute light chain cast nephropathy and there my message is crystal clear: plex first and ask questions later. Start dara VCd asap. In patient. Advocate for patients to have access even if hospital loses money.